公开(公告)号：US20180140582A1

公开(公告)日：2018-05-24

申请号：US15876619

申请日：2018-01-22

申请人： NOVARTIS AG

发明人： Jun CAO ,  Bernhard ERB ,  Robin Alec FAIRHURST ,  Arnaud GRANDEURY ,  Shinji HATAKEYAMA ,  Magdalena KOZICZAK-HOLBRO ,  Xinzhong LAI ,  Philipp LUSTENBERGER ,  Bernd Ulrich RIEBESEHL ,  Nicola TUFILLI ,  Thomas ULLRICH ,  Xiang WU ,  Jianguang ZHOU

IPC分类号： A61K31/428 ,  C07C53/10 ,  C07D277/68 ,  A61K45/06 ,  A61K31/167

CPC分类号： A61K31/428 ,  A61K31/167 ,  A61K45/06 ,  C07B2200/07 ,  C07C53/10 ,  C07D277/68 ,  Y02P20/55

摘要： The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

公开(公告)号：US20230074064A1

公开(公告)日：2023-03-09

申请号：US17858713

申请日：2022-07-06

申请人： NOVARTIS AG

发明人： Stephanie Kay DODD ,  Arnaud GRANDEURY ,  Emmanuel SUFFERT ,  Evgenia ROUSAKI

IPC分类号： C07D401/14

摘要： The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

公开(公告)号：US20230355582A1

公开(公告)日：2023-11-09

申请号：US18355618

申请日：2023-07-20

申请人： NOVARTIS AG

发明人： Bruno GALLI ,  Jean-Marie GLANTZMANN ,  Arnaud GRANDEURY ,  Klaus-Peter MOLL ,  Martin MUELLER-ZSIGMONDY ,  Karsten PUTZBACH ,  Dirk SPICKERMANN ,  Hubert THOMA ,  Mike UFER

IPC分类号： A61K31/404 ,  A61K9/28 ,  A61K9/20 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/16 ,  A61K9/50 ,  A61K47/38

CPC分类号： A61K31/404 ,  A61K9/28 ,  A61K9/2004 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/1652 ,  A61K9/1682 ,  A61K9/2072 ,  A61K9/50 ,  A61K9/5089 ,  A61K47/38

摘要： Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

公开(公告)号：US20230089503A1

公开(公告)日：2023-03-23

申请号：US17858701

申请日：2022-07-06

申请人： NOVARTIS AG

发明人： Stephanie Kay DODD ,  Arnaud GRANDEURY ,  Emmanuel SUFFERT ,  Evgenia ROUSAKI

IPC分类号： C07D401/14

摘要： The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

公开(公告)号：US20230042479A1

公开(公告)日：2023-02-09

申请号：US17424690

申请日：2020-01-23

申请人： Novartis AG

发明人： Arnaud GRANDEURY ,  Nilesh PATEL ,  Frank SCHAEFER ,  Daniel ZIMMERMANN

IPC分类号： A61K31/519 ,  C07D487/04 ,  A61K45/06

摘要： Provided herein are new crystalline form(s) of succinate salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide (also known as ribociclib), pharmaceutical compositions comprising the same, methods of treatment using the same and methods of making the same.

公开(公告)号：US20210069150A1

公开(公告)日：2021-03-11

申请号：US16898071

申请日：2020-06-10

申请人： NOVARTIS AG

发明人： Bruno GALLI ,  Jean-Marie GLANTZMANN ,  Arnaud GRANDEURY ,  Klaus-Peter MOLL ,  Martin MUELLER- ZSIGMONDY ,  Karsten PUTZBACH ,  Dirk SPICKERMANN ,  Hubert THOMA ,  Mike UFER

IPC分类号： A61K31/404 ,  A61K9/28 ,  A61K9/20 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/16 ,  A61K9/50 ,  A61K47/38

摘要： Drug products in the form of modified release formulations comprising the drug substance (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.